BioCentury
ARTICLE | Clinical News

ALN-TTR01: Preliminary Phase I data

January 2, 2012 8:00 AM UTC

Preliminary data from a placebo-controlled, dose-escalation, European Phase I trial in 31 evaluable patients with TTR-mediated amyloidosis showed that single doses of 0.01-1 mg/kg IV ALN-TTR01 were we...